Medifocus Inc. Announces Plans to Undergo Balance Sheet Restructuring
TORONTO, ON / ACCESSWIRE / September 17, 2021 / Medifocus, Inc. (OTC PINK:MDFZF) and (TSXV:MFS.H.APH) ("Medifocus" or the "Company") a...
Day: September 17, 2021
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
Expands GEN-1 Program Collaboration to Add Clinical and Commercial Batches of Investigational Vaccine LAWRENCEVILLE, N.J. and HAINAN, China, Sept. 17,...
MaxCyte Set to Join Russell 2000® Index
GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company...
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer
Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021Results show...
Better Choice Company Repurchases Approximately $1.3 Million of Common Stock through Buyback Program
TAMPA, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE American: BTTR) (“Better Choice” or “the Company”),...
Simply Better Brands Corp. Closes the Acquisition of the Crisp Group
VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the "Company" or “Simply Better Brands”) (TSX...
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company...
Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
- Conference Dates: September 20th-23rd - BETHESDA, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”,...
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021 First EVICTION...
CVRx Added to Russell 2000® and 3000® Indexes
MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing,...
Applied Molecular Transport Announces Upcoming Investor Events in September and October
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical...
Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity
BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to...
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index
WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing...
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach...
Humacyte Leadership to Present at Five Scientific Events in September
DURHAM, N.C., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable...
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”)...
Monalizumab Data From COAST Trial Presented at ESMO Congress 2021
Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the...
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies...
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor...
InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar “Accelerating The Commercialization of Rare Cannabinoids”
Registration for the September 21, 2021 event now open VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals...